ChemicalBook > CAS DataBase List > Capivasertib

Capivasertib

Product Name
Capivasertib
CAS No.
1143532-39-1
Chemical Name
Capivasertib
Synonyms
Capivasertib;4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-;CS-561;AZD5636;AZD5363;AZD5356;Capivasertinib;AZD5363 USP/EP/BP;AZD-5363; AZD 5363;AZD5363(Capivasertib)
CBNumber
CB12650349
Molecular Formula
C21H25ClN6O2
Formula Weight
428.92
MOL File
1143532-39-1.mol
More
Less

Capivasertib Property

Melting point:
161-164°C
Density 
1.381
storage temp. 
Refrigerator
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
13.93±0.50(Predicted)
form 
Solid
color 
Off-White to Pale Beige
InChIKey
JDUBGYFRJFOXQC-KRWDZBQOSA-N
SMILES
N1(C2N=CN=C3NC=CC3=2)CCC(N)(C(N[C@H](C2=CC=C(Cl)C=C2)CCO)=O)CC1
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
15406
Product name
AZD 5363
Purity
≥98%
Packaging
1mg
Price
$57
Updated
2024/03/01
Cayman Chemical
Product number
15406
Product name
AZD 5363
Purity
≥98%
Packaging
5mg
Price
$166
Updated
2024/03/01
Cayman Chemical
Product number
15406
Product name
AZD 5363
Purity
≥98%
Packaging
10mg
Price
$231
Updated
2024/03/01
Cayman Chemical
Product number
15406
Product name
AZD 5363
Purity
≥98%
Packaging
25mg
Price
$412
Updated
2024/03/01
Tocris
Product number
6978
Product name
AZD5363
Purity
≥98%(HPLC)
Packaging
25
Price
$545
Updated
2021/12/16
More
Less

Capivasertib Chemical Properties,Usage,Production

Uses

AZD5363 is used in inhibiting the proliferation of certain tumor cell lines.

Biological Activity

azd5363 is a novel, potent phosphoinositide 3-kinase (pi3k)/akt pathway inhibitor with ic50 value of ~200nm. [1]azd5363 is proved to inhibit castrate resistant prostate cancer (crpc) progression. clusterin (clu) and autophagy will be induced which may work as cytoprotective responses which can affect the downstream pi3k/akt signaling. [2] azd5363 inhibits the growth of a lot of human tumor cells in a dose dependent manner. the mode of action could be monotherapy as well as in combination with her2 inhibitors in breast cancer models. [3] it is suggested to induce cell apoptosis by measuring the expression of parp cleavage, the activity of caspase 3, et al. [1]most importantly, azd5363 can target the pi3k/akt-pathway in vivo significantly, thus reducing the serum psa-levels and tumor volume, finally, it could postpone the progression to crpc.[1]

Synthesis

1143534-59-1

3680-69-1

1143532-39-1

General steps: 1. N,N-diisopropylethylamine (1.676 mL, 9.62 mmol) was added under nitrogen protection to a solution containing (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)piperidine-4-carboxamide (Intermediate 49) (1 g, 3.21 mmol) and 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (0.493 g 3.21 mmol) in a solution of n-butanol (15 mL). 2. The reaction mixture was stirred at 60 °C for 18 hours. 3. After completion of the reaction, the reaction mixture was diluted with ethyl acetate (50 mL) and washed sequentially with water (25 mL) and saturated saline (25 mL). 4. The organic layer was separated, dried with anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to obtain the crude product. 5. The crude product was purified by fast silica gel column chromatography using dichloromethane with a gradient elution containing 0 to 6% methanol and ammonia. 6. The purified fraction was collected and concentrated to dryness under reduced pressure to afford (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (842 mg) as a white foamy solid. 7. The resulting product was dissolved in ethyl acetate (7 mL) and stirred for 18 hours. 8. The precipitated solid was collected by filtration, washed with a small amount of ethyl acetate and dried in a vacuum oven at 55 °C for 18 h. (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (0.585 g, 42.5% yield) was obtained as a white solid. Mass spectrum (electrospray positive ion mode): m/z (ES+) (M + H)+ = 429; HPLC retention time tR = 1.60 min. 1H NMR (400.13 MHz, DMSO-d6) δ 1.39-1.47 (2H, m), 1.80-2.02 (4H, m), 2.17 (2H, s), 3.35-3.40 (2H, m), 3.50-3.59 (2H, m), 4.34-4.41 (2H, m), 4.53 (1H, t), 4.88 (1H, d), 6.57 (1H, m), 7.14-7.16 (1H, m), 7.31-7.37 (4H, m), 8.12 (1H, s), 8.42 (1H, d), 11.62 (1H, s).

in vivo

Oral dosing of Capivasertib (AZD5363) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts (PRAS40 phosphorylation EC50 ~0.1 μM total plasma exposure), reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[18F]fluoro-2-deoxy-D-glucose (18F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of Capivasertib caused dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models. Capivasertib also significantly enhances the antitumor activity of RP-56976 and GW572016 in breast cancer xenografts[1].

target

Akt

IC 50

Akt1: 3 nM (IC50); Akt2: 7 nM (IC50); Akt3: 7 nM (IC50); P70S6K: 6 nM (IC50); PKA: 7 nM (IC50); ROCK2: 60 nM (IC50); ROCK1: 470 nM (IC50); Autophagy

storage

Store at -20°C

References

[1] thomas c, crafter c, davies b, zoubeidi a, gleave me. azd5363, a novel akt inhibitor, delays prostate cancer progression. the journal of urology. may 2011. 185(4s): e292-293.
[2] kumano m, zhang f, shiota m, crafter c, davies b, zoubeidi a, gleave m. clusterin knockdown enhances antitumor activity of a novel akt inhibitor, azd5363, through inhibition of autophagy in prostate cancer. the journal of urology. may 21 2012. e392.
[3] davies br, greenwood h, dudley p, et al. preclinical pharmacology of azd5363, an inhibitor of akt: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. mol. cancer ther. arp 2012. 11: 873.

Capivasertib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Capivasertib Suppliers

China 211 India 2 United States 21 Global 234
Jiangsu Magic Biotechnology Co., Ltd
Tel
13921770081
Email
svp01@magicbiotech.cn
Country
China
ProdList
500
Advantage
58
Chunchuang (Wuhan) Technology Co., Ltd
Tel
15727060112
Email
yutianchun2007@126.com
Country
China
ProdList
9814
Advantage
58
Arizest(Shanghai)Pharmatech Co.,Ltd
Tel
13671599112
Email
geshi.zhuang@synovent.cn
Country
China
ProdList
426
Advantage
58
Bayee Biotech (Anqing) Co., Ltd.
Tel
0556-5032306 18917961636
Email
wtx@bayeebio.com
Country
China
ProdList
239
Advantage
61
Olix (Shanghai) Pharmaceutical Technology Co., Ltd
Tel
17316404525 17316404525
Email
209533805@qq.com
Country
China
ProdList
9766
Advantage
58
Shanghai WELI Biotechnology Co.,Ltd
Tel
18621923808
Fax
0530-5859609
Email
ytt@welidream.com
Country
China
ProdList
37
Advantage
58
WuHu Linze pharmaceutical Co.,Ltd.
Tel
18356571950
Fax
-
Email
2030235803@qq.com
Country
China
ProdList
94
Advantage
58
JIANGXI HANHE PHARMACEUTICAL CO.,LTD
Tel
18721221949
Email
zhangle@jxhhzy.com
Country
China
ProdList
102
Advantage
58
CHANGZHOU PHARMACEUTICAL FACTORY
Tel
519-88821493 18915891730
Email
shm@czpharma.com
Country
China
ProdList
170
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
More
Less

View Lastest Price from Capivasertib manufacturers

Apeloa production Co.,Limited
Product
Capivasertib (AZD5363) 1143532-39-1
Price
US $1.00/g
Min. Order
1g
Purity
99%
Supply Ability
11000
Release date
2024-06-17
Career Henan Chemical Co
Product
AZD5363 1143532-39-1
Price
US $2.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
100kg
Release date
2018-12-24

1143532-39-1, CapivasertibRelated Search:

2-amino-4-chlorobenzamide 2-Amino-5-chlorobenzophenone Everolimus 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol MK-2206 2HCl GDC-0068 Trametinib Rapamycin

  • AZD5356
  • AZD5363
  • 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide
  • 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-
  • 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide AZD5363
  • AZD 5363 dihydrochloride
  • AZD5363;AZD-5363;AZD 5363
  • (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidi
  • Capivasertib
  • AZD5363, 99%, a potent pan-AKT kinase inhibitor
  • AZD5636
  • AZD5363(Capivasertib)
  • CAPIVASERTIB (AZD5363)
  • CS-561
  • AZD-5363; AZD 5363
  • 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
  • AZD5363 USP/EP/BP
  • (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
  • Capivasertib AZD5363 AZD-5363
  • Autophagy,AZD 5363,Inhibitor,inhibit,AZD-5363,PKB,Akt,Capivasertib,Protein kinase B
  • Capivasertib, 10 mM in DMSO
  • Capivasertinib
  • 1143532-39-1
  • C21H25ClN6O2
  • Inhibitors
  • Akt
  • mTOR
  • PI3K
  • PI3K/Akt/mTOR
  • API